tizanidine has been researched along with Cerebral Palsy, Athetoid in 11 studies
tizanidine: RN given refers to parent cpd; structure
tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cerebral palsy is usually spastic, and baclofen, benzodiazepines and tizanidine are considered as oral treatments." | 9.13 | [Protocol for tizanidine use in infantile cerebral palsy]. ( Arroyo Riaño, O; Benavente Valdepeñas, A; Palazón García, R, 2008) |
| " Following botulinum toxin A treatment, clinical improvement led to the gradual reduction of baclofen or tizanidine dosing to one-third of the former dose." | 5.43 | Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity. ( Aksoy, SN; Dai, AI; Demiryürek, AT, 2016) |
| "Cerebral palsy is usually spastic, and baclofen, benzodiazepines and tizanidine are considered as oral treatments." | 5.13 | [Protocol for tizanidine use in infantile cerebral palsy]. ( Arroyo Riaño, O; Benavente Valdepeñas, A; Palazón García, R, 2008) |
| "For localized/segmental spasticity, botulinum toxin type A is established as an effective treatment to reduce spasticity in the upper and lower extremities." | 2.46 | Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child ( Aisen, M; Ashwal, S; Delgado, MR; Fehlings, DL; Hirtz, D; McLaughlin, J; Morrison, LA; Shrader, MW; Tilton, A; Vargus-Adams, J, 2010) |
| "While in some children, spasticity may adversely impact the motor abilities, in others, it may help maintain posture and ability to ambulate." | 2.43 | Pharmacologic interventions for reducing spasticity in cerebral palsy. ( Patel, DR; Soyode, O, 2005) |
| " Following botulinum toxin A treatment, clinical improvement led to the gradual reduction of baclofen or tizanidine dosing to one-third of the former dose." | 1.43 | Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity. ( Aksoy, SN; Dai, AI; Demiryürek, AT, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, AI | 2 |
| Aksoy, SN | 1 |
| Demiryürek, AT | 1 |
| Wasay, M | 1 |
| Awan, S | 1 |
| Delgado, MR | 1 |
| Hirtz, D | 1 |
| Aisen, M | 1 |
| Ashwal, S | 1 |
| Fehlings, DL | 1 |
| McLaughlin, J | 1 |
| Morrison, LA | 1 |
| Shrader, MW | 1 |
| Tilton, A | 1 |
| Vargus-Adams, J | 1 |
| Chung, CY | 1 |
| Chen, CL | 1 |
| Wong, AM | 1 |
| Patel, DR | 1 |
| Soyode, O | 1 |
| Palazón García, R | 1 |
| Benavente Valdepeñas, A | 1 |
| Arroyo Riaño, O | 1 |
| Knutsson, E | 1 |
| Shumilina, AP | 1 |
| Guzeva, VI | 1 |
| Skoromets, AA | 1 |
| Maksimov, OG | 1 |
| Secheĭko, MV | 1 |
| Andriĭchuk, EL | 1 |
| Brin, IL | 1 |
| Kurenkov, AL | 1 |
| Gotlib, VIa | 1 |
| Autti-Rämö, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Radial Extracorporeal Shock Wave Therapy for Management of Spasticity in Patients With Cerebral Palsy[NCT05702606] | 73 participants (Actual) | Interventional | 2021-06-10 | Completed | |||
| Sensory-Motor Rehabilitation Post Stroke[NCT02369770] | 140 participants (Anticipated) | Interventional | 2019-04-26 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for tizanidine and Cerebral Palsy, Athetoid
| Article | Year |
|---|---|
Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child
Topics: Adolescent; Botulinum Toxins, Type A; Cerebral Palsy; Child; Clonidine; Diazepam; Humans; Muscle Rel | 2010 |
Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child
Topics: Adolescent; Botulinum Toxins, Type A; Cerebral Palsy; Child; Clonidine; Diazepam; Humans; Muscle Rel | 2010 |
Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child
Topics: Adolescent; Botulinum Toxins, Type A; Cerebral Palsy; Child; Clonidine; Diazepam; Humans; Muscle Rel | 2010 |
Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child
Topics: Adolescent; Botulinum Toxins, Type A; Cerebral Palsy; Child; Clonidine; Diazepam; Humans; Muscle Rel | 2010 |
Pharmacotherapy of spasticity in children with cerebral palsy.
Topics: Baclofen; Benzodiazepines; Cerebral Palsy; Child; Clonidine; Dantrolene; Humans; Muscle Spasticity; | 2011 |
Pharmacologic interventions for reducing spasticity in cerebral palsy.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Age Factors; Anti-Infective Agents, Local; Baclofen | 2005 |
[Treatment of spasticity].
Topics: Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Clonidine; Humans; Injections, Spinal; Muscle Re | 1999 |
4 trials available for tizanidine and Cerebral Palsy, Athetoid
| Article | Year |
|---|---|
Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity.
Topics: Administration, Oral; Adolescent; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Chi-Square Dis | 2008 |
[Protocol for tizanidine use in infantile cerebral palsy].
Topics: Cerebral Palsy; Child; Child, Preschool; Clonidine; Drug Administration Schedule; Female; Humans; In | 2008 |
[The use of sirdalud in the treatment of spasticity in infantile cerebral palsy].
Topics: Adolescent; Anticonvulsants; Cerebral Palsy; Child; Child, Preschool; Clonidine; Dose-Response Relat | 1999 |
[The use of sirdalud in cerebral palsy in children].
Topics: Adolescent; Cerebral Palsy; Child; Clonidine; Dose-Response Relationship, Drug; Electromyography; Fe | 1999 |
3 other studies available for tizanidine and Cerebral Palsy, Athetoid
| Article | Year |
|---|---|
Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
Topics: Administration, Oral; Adolescent; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, | 2016 |
Analysis of gait and isokinetic movements for evaluation of antispastic drugs or physical therapies.
Topics: Cerebral Palsy; Clonidine; Electromyography; Gait; Humans; Motor Neurons; Muscle Contraction; Muscle | 1983 |
[Sirdalud in the practice of the pediatric neurologist].
Topics: Adolescent; Cerebral Palsy; Child; Clonidine; Drug Evaluation; Humans; Muscle Relaxants, Central; Mu | 1997 |